Effects of the German reference drug program on ex-factory prices of prescription drugs: A panel data approach

Health Economics

Volumn 18, Issue 4, 2009, Pages 421-436

  Augurzky, Boris ^a,b   Göhlmann, Silja ^a   Greß, Stefan ^c   Wasem, Jürgen ^d  

^a RWI LEIBNIZ INSTITUTE FOR ECONOMIC RESEARCH   (Germany)

^b IZA   (Germany)

^c UNIVERSITY OF APPLIED SCIENCES   (Germany)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Drug prices; Price elasticity; Reference drug program; Temporal development

Indexed keywords

ARTICLE; COMMERCIAL PHENOMENA; COST BENEFIT ANALYSIS; COST CONTROL; DRUG COST; DRUG MARKETING; GERMANY; HEALTH ECONOMICS; HEALTH INSURANCE; HEALTH PROGRAM; PHARMACEUTICAL CARE; PRESCRIPTION; PRIORITY JOURNAL;

COMMERCE; COST CONTROL; DRUG COSTS; DRUG INDUSTRY; ECONOMIC COMPETITION; ECONOMICS, PHARMACEUTICAL; GERMANY; MODELS, ECONOMETRIC; NATIONAL HEALTH PROGRAMS; PRESCRIPTION FEES;

EID: 67149137843     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.1376     Document Type: Article

References (12)

1. Danzon PM, Ketcham JD. 2003. Reference pricing of pharmaceuticals for medicare: evidence from Germany, the Netherlands and New Zealand. NBER Working Paper Series 10007; 1-47.
2. Greß S, Niebuhr D, May U, Wasem J. 2007. Reform of prescription drug reimbursement and pricing in the German social health insurance market - a comparison of three scenarios. PharmacoEconomics 25(6): 443-454.
3. Grootendorst PV, Marshall JK, Holbrook AM, Dolovich LR, O'Brien BJ, Levy AR. 2005. The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs. Health Services Research 40(5) Pt 1: 1297-1317.
4. Pavcnik N. 2002. Do pharmaceutical prices respond to potential patient out-of-pocket expenses? The Rand Journal of Economics 33(3): 469-487.
5. Puig-Junoy J. 2005. What is required to evaluate the impact of pharmaceutical reference pricing? Applied Health Economics Health Policy 4(2): 87-98.
6. Puig-Junoy J. 2007. The impact of generic reference pricing interventions in the statin market. Health Policy. DOI:10.1016/ j.healthpol.2007.02.010.
7. Schneeweiss S. 2007. Reference drug programs: effectiveness and policy implications. Health Policy 81: 17-28.
8. Schneeweiss S, Dormuth C, Grootendorst P, Soumerai SB, Maclure M. 2004. Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents. Medical Care 42(7): 653-660.
9. Schneeweiss S, Soumerai SB, Maclure M, Dormuth C, Walker AM, Glynn RJ. 2003. Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers. Clinical Pharmacology and Therapeutics 74(4): 388-400.
10. Schneeweiss S, Walker AM, Glynn RJ, McLure M, Dormuth C, Soumerai SB. 2002. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. The New England Journal of Medicine 346(11): 822-829.
11. Stargardt T, Schreyögg J, Busse R. 2005. Arzneimittelfestbeträge: Gruppenbildung, Preisberechnung mittels Regressionsverfahren und Wirkungen. Das Gesundheitswesen 67: 468-477.
12. Zweifel P, Crivelli L. 1996. Price regulation of drugs: lessons from Germany. Journal of Regulatory Economics 10: 257-273.